PROCEPT BioRobotics Corp (PRCT) stock
PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3049% below fair value
$25.18+1.40 (+5.89%)
Close on Nov 18, 2026Market cap $1.44BP/E –Yield –
PROCEPT BioRobotics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
PROCEPT BioRobotics's free cash flow for the twelve months ending Jun 30, 2026 was -$84.93M. For fiscal 2025 it was -$58.34M. The highest annual figure on record is -$48.58M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.34M | – |
| FY2024 | Dec 31, 2024 | -$103.62M | – |
| FY2023 | Dec 31, 2023 | -$133.21M | – |
| FY2022 | Dec 31, 2022 | -$83.04M | – |
| FY2021 | Dec 31, 2021 | -$57.93M | – |
| FY2020 | Dec 31, 2020 | -$48.58M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.04M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.86M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.45M | – |
See a number that looks wrong?